

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: RECOMBINANT *CANDIDA RUGOSA* LIPASES
APPLICANT: JEI-FU SHAW, GUAN-CHIUN LEE AND
SHYE-JYE TANG

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL270011907US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit August 31, 2001

Signature *Samantha Bell*

Samantha Bell
Typed or Printed Name of Person Signing Certificate

Recombinant *Candida rugosa* Lipases

BACKGROUND

Lipase (EC 3.1.1.3) is able to catalyze a wide range of chemical reactions, which include nonspecific and stereo-specific hydrolysis, esterification, *trans*-esterification, and interesterification. In addition, it catalyzes the hydrolysis of an ester bond at water-lipid interface. See, e.g., Ader *et al.* (1997) *Methods Enzymol.* 286: 351-385; Gandhi (1997) *J Am Oil Chem. Soc.* 74: 621-634; Klivanov (1990) *Acc. Chem. Res.* 23: 114-120; Shaw *et al.* (1990) *Biotechnol. Bioeng.* 35: 132-137; and Wang *et al.* (1988) *Biotechnol. Bioeng.* 31: 628-633.

Due to its catalytic abilities, a *Candida rugosa* lipase, among commercial lipases, is widely used in bioindustries. Generally, crude *C. rugosa* lipases are applied in almost all biocatalytic applications, however, enzymes from various suppliers have been reported to show variations in their catalytic efficiency and stereospecificity. See Barton *et al.* (1990) *Enzyme Microb. Technol.* 12: 577-583. Several lipase isomers (i.e., isozymes) have been isolated from the crude *C. rugosa* lipase, and the lipase isozymes were shown to be different in catalytic efficiency and specificity. See Shaw *et al.* (1989) *Biotechnol. Lett.* 11: 779-784; Rúa *et al.* (1993) *Biochem. Biophys. Acta* 1156: 181-189; Diczfalussy *et al.* (1997) *Arch. Biochem. Biophys.* 348: 1-8.

To date, five lipase-encoding genomic sequences from *C. rugosa* have been characterized. See, for example, Longhi *et al.* (1992) *Biochim. Biophys. Acta* 1131: 227-232; and Lotti *et al.* (1993) *Gene* 124: 45-55. The five lipase-encoding genes (LIP1, 2, 3, 4, and 5) have been isolated from a *SacI* genomic library of the yeast *C. rugosa* by colony hybridization. The five genes encode for mature proteins of 534 residues with putative signal peptides of 15 (in LIP1, 3, 4, and 5) and 14 (in LIP 2) amino acids in length, respectively. The five deduced amino acid sequences share an overall identity of 66% and similarity of 84%. Due to a high sequence homology among the five deduced amino acid sequences and the differential expression level of the five lipase genes (Lee *et al.* (1999) *Appl. Environ. Microbiol.* 65: 3888-3895), it is difficult to purify each isozyme directly from the cultures of *C. rugosa* on a preparative scale for industrial applications.

Further, although these isozymes are conserved at a catalytic triad (including amino acids S209, H449, and E341) and at the sites involved in disulfide bonds formation (including amino acids C60, C97 and C268, C277), they differ in N-glycosylation sites, isoelectric points, and some other features in their hydrophobic profiles. In addition, each of the isozymes may account for certain properties, such as catalytic efficiency and specificity. See Chang *et al.* (1994) *Biotechnol. Appl. Biochem.* 19: 93-97. Accordingly, cloning and functional expression of a *C. rugosa* lipase isozyme are desirable for producing a pure isozyme with certain properties for industrial applications.

However, *C. rugosa* is a dimorphic yeast in which the triplet CTG, a universal codon for leucine, is read as serine. As a result, the functional expression of a *C. rugosa* isozyme becomes unfeasible in a common host cell (in which CTG is read as leucine). See Kawaguchi *et al.* (1989) *Nature* 341: 164-166.

SUMMARY

This invention relates to a nucleic acid that can be used to functionally express a heterologous *C. rugosa* lipase in a common host cell.

In one aspect, the present invention features an isolated nucleic acid that includes a mutant DNA encoding a *C. rugosa* lipase. The mutant DNA is at least 80% (e.g., at least 85%, 90%, or 95%) identical to a wild-type DNA encoding the *C. rugosa* lipase, and includes at least 12 (e.g., 13, 15, 17, or all) universal serine codons corresponding to CTG codons in the wild-type DNA. Each of the CTG codon is read as serine in *C. rugosa*. Each of the universal serine codons, independently, is TCT, TCC, TCA, TCG, AGT, or AGC. The term "*C. rugosa* lipase" as used herein refers to a pure isozyme, and includes native *C. rugosa* lipases 1, 2, 3, 4, 5, and 8, as well as their variants. Examples of the just-described isolated nucleic acid include, but are not limited to, SEQ ID NOs:1, 3, 5, 7, and 9, the corresponding amino acid sequences of which are SEQ ID NOs:2, 4, 6, 8, and 10, respectively.

The mutant DNA can be a DNA of SEQ ID NO:1, 3, 5, 7, or 9, or a degenerate variant thereof. The degenerate variant refers to any other DNA sequence which encodes, based on universal codons, the same polypeptide as that encoded by the SEQ ID NO:1, 3, 5, 7, or 9. The mutant DNA can also be a DNA encoding a polypeptide sequence that is at least

90% (e.g., 95%, 98% or 100%) identical to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, or 10. Indeed, the polypeptide sequence need not be a full length of the just-described amino acid sequence as long as its intended catalytic ability in the polypeptide has not been completely abolished. For example, a mutant DNA is a functional fragment containing at least 1070 nucleotides (e.g., 1200, or 1500 nucleotides) of the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, or 9; or a sequence encoding a functional fragment of a polypeptide containing the amino acid sequence of SEQ ID NO:2, 4, 6, 8, or 10, wherein the fragment includes at least 350 amino acids (e.g., 400, or 500 amino acids).

The term “isolated nucleic acid” refers to a nucleic acid the structure of which is not identical to that of any naturally occurring nucleic acid or to that of any fragment of a naturally occurring genomic nucleic acid spanning more than three separate genes. The term therefore covers, for example, (a) a DNA which has the sequence of part of a naturally occurring genomic DNA molecule but is not flanked by both of the coding sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. The above-described isolated nucleic acid of this invention can be introduced into and expressed in a microorganism, which is also within the scope of this invention. An example of the microorganism is a bacterium (e.g., *Escherichia coli*) or yeast (e.g., *Pichia pastoris*).

The “percent identity” (or “percent homology”) of two amino acid sequences or of two nucleic acids can be determined using the algorithm of Thompson *et al.* (CLUSTAL W, 1994 *Nucleic Acids Res.* 22: 4673-4680). An amino acid sequence or a nucleotide sequence can also be used as a “query sequence” to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the algorithm of Karlin and Altschul (1990 *Proc. Natl. Acad. Sci. USA* 87: 2264-2268), modified as in Karlin and Altschul (1993 *Proc. Natl. Acad. Sci. USA* 90: 5873-5877). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.* (1990 *J. Mol. Biol.*

215: 403-410). BLAST nucleotide searches are performed with the NBLAST program, score = 100, wordlength = 12. BLAST protein searches are performed with the XBLAST program, score = 50, wordlength = 3. Where gaps exist between two sequences, Gapped BLAST is utilized as described in Altschul *et al.* (1997 *Nucleic Acids Res.* 25: 3389-3402). When
 5 utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used. See <http://www.ncbi.nlm.nih.gov/>.

In another aspect, this invention features a method for preparing a mutant DNA encoding a *C. rugosa* lipase. The method includes providing a wild-type DNA encoding a *C. rugosa* lipase; and conducting PCR amplification by mixing the wild-type DNA, a DNA
 10 polymerase, a pair of external primers encompassing the entirety of the wild-type DNA, and a number of pairs of internal primers respectively encompassing fragments of the wild-type DNA. An "external primer" is a PCR primer designed to amplify the entirety of a mutant DNA, and an "internal primer" is a PCR primer designed to amplify a fragment of the mutant DNA.; a primer can operate both as an external and as an internal primer. Each of the
 15 internal primers includes one or more of universal codons and anticodons for serine selected from TCT, TCC, TCA, TCG, AGT, AGC, AGA, GGA, TGA, CGA, ACT, and GCT, in which the universal codons and anticodons correspond to at least 12 CTG codons in the wild-type DNA. Further, each internal primer overlaps with another internal or external primer in a manner that a mutant DNA encoding the *C. rugosa* lipase is obtained.

20 In a further aspect, this invention features a chimeric *C. rugosa* lipase including a substrate interacting domain of a first *C. rugosa* lipase and a non-substrate interacting domain (e.g., a carboxylesterase domain) of a second *C. rugosa* lipase. For example, the second *C. rugosa* lipase is a polypeptide of SEQ ID NO:6, and the first *C. rugosa* lipase is a polypeptide of SEQ ID NO:2, 4, 8, or 10.

25 Also within the scope of this invention is the use of afore-mentioned nucleic acid for the manufacture of a *C. rugosa* lipase for biocatalytic applications.

Other features, objects, and advantages of the invention will be apparent from the description and from the claims.

DETAILED DESCRIPTION

This invention relates to an isolated nucleic acid that includes a mutant DNA, which is at least 80% identical to a wild-type DNA encoding a *C. rugosa* lipase.

Set forth below are the mutant nucleic acid sequences of *C. rugosa* lipase 2, *C. rugosa* lipase 3, *C. rugosa* lipase 4, *C. rugosa* lipase 5, and *C. rugosa* lipase 8, wherein all the CTG codons corresponding to serine in the wild-type DNA have been replaced by universal serine codons. The mutated nucleotides are represented in black background. Also shown are the encoded amino acid sequences.

C. rugosa lipase 2

10
 CGACACCATCACCAGTCTCAACGCC 90
 S M N S R G P A G R L G S V P T A T L A N G D T I T G L N A
 15
 ATTGTC AACGAAAAGTTTCTCGGCATACCGTTTGCCGAGCCGCCCGTGGGCA CTCCGCTTCAAG
 CCGCCCGTGCCGTACTCGGCGTCG 180
 I V N E K F L G I P F A E P P V G S L R F K P P V P Y S A S
 CTCAACGGCCAGCAGTTTACC TACGGCCCG TGCATGCAGATGAACCCTATGGGCTCGTTT
 GAGGACACACTTCCCAAGAATGCG 270
 L N G Q Q F T S Y G P S C M Q M N P M G S F E D T L P K N A
 20
 C A TTGGTGCTCCAGTCCAAGATCTTCCAAGTGGTGCTTCCCAACGACGAGGACTGTCTCACC
 ATCAACGTGATCCGGCCGCCCGGC 360
 L D L V L Q S K I F Q V V L P N D E D C L T I N V I R P P G
 ACCAGGGCCAGTGCTGGTCTCCCGGTGATGCTCTGGATCTTTGGCGGTGGGTTTGAGCTTGGCGGC
 TCCAGCCTCTTCCAGGAGACCAG 450
 25
 T R A S A G L P V M L W I F G G G F E L G G S S L F P G D Q
 ATGGTGGCCAAGAGCGTGCTCATGGGTAAACCGGTGATCCACGTGAGCATGAACTACCGCGTGGC
 GTCATGGGGGTTCTTGGCCGGCCCC 540
 M V A K S V L M G K P V I H V S M N Y R V A S W G F L A G P
 GACATCCAGAACGAAGGCAGCGGGAACGCCGGCTTGCATGACCAGCGCTTGGCCATGCAGTGGGT
 30
 GGCGGACAACATTGCTGGGTTTGGC 630
 D I Q N E G S G N A G L H D Q R L A M Q W V A D N I A G F G
 GGCGACCCGAGCAAGGTGACCATATACGGCGAG GCGGGCAGCATGTCGACGTTTGTGCACCT
 TGTGTGGAACGACGGCGACAACACG 720
 G D P S K V T I Y G E S A G S M S T F V H L V W N D G D N T
 35
 TACAACGGCAAGCCGTTGTTCCGCGCCGCCATCATGCAG GGCTGCATGGTGCCG GACCCG
 GTGGACGGCACGTACGGCACCGAG 810
 Y N G K P L F R A A I M Q S G C M V P S D P V D G T Y G T E
 ATCTACAACCAGGTGGTGGCGTCTGCCGGGTGTGGCAGTGCCAGCGACAAGCTCGCGTGCTTGCG
 CGGCCTT CAGGACACGTTGTAC 900

I Y N Q V V A S A G C G S A S D K L A C L R G L S Q D T L Y
CAGGCCACGAGCGACACGCCCGGCGTGTGGCGTACCCGTCGTTGCGGTTG [REDACTED] TATCTCCCGCGG
CCCGACGGCACCTTCATCACCGAC 990

Q A T S D T P G V L A Y P S L R L S Y L P R P D G T F I T D
5 GACATGTATGCCTTGGTGCAGGACGCAAGTACGCACACGTGCCGGTGATCATCGGCGACCAGAA
CGACGAGGGCACTTTGTTTGGGCTC 1080

D M Y A L V R D G K Y A H V P V I I G D Q N D E G T L F G L
[REDACTED] TTGAACGTGACCACAGATGCTCAGGCACGGGCGTACTTCAAGCAG [REDACTED] TTCATCCACGCC
AGCGATGCGGAGATCGACACGTTG 1170

10 S S L N V T T D A Q A R A Y F K Q S F I H A S D A E I D T L
ATGGCGGCGTACACCAGCGACATCACCCAGGGT [REDACTED] CCGTTCGACACCGGCATCTTCAATGCCATC
ACCCCGCAGTTCAAACGGATC [REDACTED] 1260

M A A Y T S D I T Q G S P F D T G I F N A I T P Q F K R I S
15 GCGTTGCTTGGCGACCTTGCCTTCACGCTTGCCTGCTGCTACTTCCTCAACTACTACCAGGGCGGC
ACCAAGTACTCGTT [REDACTED] CTC [REDACTED] AAG 1350

A L L G D L A F T L A R R Y F L N Y Y Q G G T K Y S F L S K
CAGCTT [REDACTED] GGGTTGCCCGTCTTGGGCACCTTCCACGGCAACGACATCATCTGGCAGGACTACTTG
GTGGGCAGCGGCAGTGTGATCTAC 1440

20 Q L S G L P V L G T F H G N D I I W Q D Y L V G S G S V I Y
AACAACGCGTTCATTGCGTTTGCCAACGACCTCGACCCGAACAAGGCGGGCTTGTGGACCAACTG
GCCACGTACACCAGCAG [REDACTED] CAG 1530

N N A F I A F A N D L D P N K A G L W T N W P T Y T S S S Q
[REDACTED] GGCAACAACCTTGATGCAGATCAACGGCTTGGGGTTGTACACCGGCAAGGACAACCTCCGCCC
GGATGCGTACAGCGCCCTCTTTCC 1620

25 S G N N L M Q I N G L G L Y T G K D N F R P D A Y S A L F S
AACCCGCC [REDACTED] TTCTTTGTG 1641 (SEQ ID NO:1)

N P P S F F V (SEQ ID NO:2)

C. rugosa lipase 3

30 [REDACTED] G [REDACTED] CCCACCGCCAAGCTCGCCAACGG
CGACACCATCACCGGTCTCAACGCC 90

S M N S R G P A G R L G S V P T A K L A N G D T I T G L N A
ATCATCAACGAGGCGTTCTCTCGGCATTCCCTTTGCCGAGCCGCCGGTGGGCAACCTCCGCTTCAAG
GACCCTGTGCCGTACTCTGGCTCG 180

35 I I N E A F L G I P F A E P P V G N L R F K D P V P Y S G S
CTCAACGGCCAGAAGTT [REDACTED] ACT [REDACTED] TACGGCCCG [REDACTED] TGCATGCAGCAGAACCCCGAGGGGCACGTTT
GAAGAGAACCTTGGCAAGACGGCA 270

L N G Q K F T S Y G P S C M Q Q N P E G T F E E N L G K T A
40 CTCGACTTGGTGTATGCAGTCCAAGGTGTTCCAGGCGGTGCTTCCCCAGAGTGAGGACTGCCTCACC
ATCAACGTGGTGCAGGCCCGCCGGGC 360

L D L V M Q S K V F Q A V L P Q S E D C L T I N V V R P P G

ACCAAGGCGGGCGCCAACCTCCCGGTCATGCTCTGGATCTTTGGCGGTGGGTTTGAGATCGGCAG
CCCCACCATCTTCCCTCCCGCCAG 450

T K A G A N L P V M L W I F G G G F E I G S P T I F P P A Q

5 ATGGTCACCAAGAGTGTGCTCATGGGCAAGC■CATCATCCACGTGGCCGTCAACTACCGTGTTCG
CTCGTGGGGGTTCTTGGCTGGTGAT 540

M V T K S V L M G K H I I H V A V N Y R V A S W G F L A G D

GACATCAAGGCCGAGGGCAGCGGGAACGCCGGCTTGAAGGACCAGCGTTTGGGCATGCAGTGGG
TGGCAGACAACATTGCCGGGTTTCGGC 630

D I K A E G S G N A G L K D Q R L G M Q W V A D N I A G F G

10 GGCGACCCGAGCAAGGTGAC■ATCTTTGGCGAG■GCGGGCAGCATGTCCGTGTTGTGCCACCTC
ATCTGGAACGACGGCGACAACAG 720

G D P S K V T I F G E S A G S M S V L C H L I W N D G D N T

TACAAGGGCAAGCCGTTGTTCCGCGCGGGCATCATGCAG■GGAGCCATGGTGCCG■GACCC
GGTGACGGCACGTACGGCAACGAG 810

15 Y K G K P L F R A G I M Q S G A M V P S D P V D G T Y G N E

ATCTACGACCTCTTTGTCTCGAGTGTGGCTGTGGCAGCGCCAGCGACAAGCTCGCGTGCTTGCGC
AGTGCG■AGCGACACCTTGCTC 900

I Y D L F V S S A G C G S A S D K L A C L R S A S S D T L L

20 GATGCCACCAACAACACTCCTGGGTTCTTGGCGTACTCCTCGTTGCGGTTG■TA■CT■CC■CGG
CCCGACGGCAAGAACATCACCGAT 990

D A T N N T P G F L A Y S S L R L S Y L P R P D G K N I T D

GACATGTACAAGTTGGTGCGCGACGGCAAGTATGCAAGCGTTCCCGTGATCATTGGCGACCAGAA
CGACGAGGGCACCATCTTTGG■CTC 1080

D M Y K L V R D G K Y A S V P V I I G D Q N D E G T I F G L

25 ■TTGAACGTGACCACGAATGCTCAGGCCCGTGCTTACTTCAAGCAG■TTCATCCACGCC
AGCGACGCGGAGATCGACACCTTG 1170

S S L N V T T N A Q A R A Y F K Q S F I H A S D A E I D T L

ATGGCGGCGTACCCCCAGGACATCACCCAGGGT■CCGTTGACAC■GG■T■TCAACGC■TC
ACCCCGCAGTTCAAGAGAATC■ 1260

30 M A A Y P Q D I T Q G S P F D T G V L N A L T P Q F K R I S

GCGGTGCTCGGCGACCTTGCAATTCATCCACGCCCGCGCTACTTCCTCAACCACTTCCAGGGCGGC
ACCAAGTACTCGTTCCTC■AAG 1350

A V L G D L A F I H A R R Y F L N H F Q G G T K Y S F L S K

35 CAGCTC■GGGTGCCAATCATGGGCACCTTCCATGCCAACGACATTGTGTGGCAGGACTACTTG
TTGGGAAGCGGCAGCGTCATCTAC 1440

Q L S G L P I M G T F H A N D I V W Q D Y L L G S G S V I Y

AACAACGCGTTTATCGCGTTCGCCACCGACTTGGACCCCAACACCGCGGGGTTGTTGGTGAAGT
GCCCAAGTACACCAGCAGC■CAG 1530

N N A F I A F A T D L D P N T A G L L V N W P K Y T S S S Q

40 ■GGCAACAACCTTGATGATGATCAACGCCTTGGGCTTGTACACCGGCAAGGACAACCTTCCGCAC
CGCTGGCTACGACGCGTTGATGACC 1620

S G N N L M M I N A L G L Y T G K D N F R T A G Y D A L M T

AACCCG [REDACTED] TTCTTTGTG 1641 (SEQ ID NO:3)
 N P S S F F V (SEQ ID NO:4)

C. rugosa lipase 4

5 [REDACTED] G [REDACTED] CCCACTGCCACGCTCGCCAACGG
 CGACACCATCACCGGTCTCAACGCC 90
 S M N S R G P A G R L G S V P T A T L A N G D T I T G L N A
 ATCATCAACGAGGCGTTTCTCGGTATTCCCTTTGCTCAGCCGCCGGTGGGCAACCTCCGCTTCAAG
 CCGCCTGTGCCGTACTCGGCGTCT 180
 10 I I N E A F L G I P F A Q P P V G N L R F K P P V P Y S A S
 CTCAATGGTCAGAAGTTTACT [REDACTED] GTATGGCCCT [REDACTED] GTGCATGCAGATGAACCCATTGGGCAACTGG
 GACTCCTCGCTTCCCAAGGCTGCC 270
 L N G Q K F T S Y G P S C M Q M N P L G N W D S S L P K A A
 ATCAAC [REDACTED] TTGATGCAGTCCAAGCTCTTCCAGGCGGTGCTTCTAACGGCGAGGACTGTCTCACC
 15 ATCAACGTGGTGCGGCCG [REDACTED] GGC 360
 I N S L M Q S K L F Q A V L P N G E D C L T I N V V R P S G
 ACCAAGCCGGGTGCCAACCTCCCCGTGATGGTGTGGATTTTGGCGGGCGGGTTTGAGGTTGGCGGC
 TCCAGTCTCTTCCCTCCCGCACAG 450
 T K P G A N L P V M V W I F G G G F E V G G S S L F P P A Q
 20 ATGATCACCGCCAGCGTGCTTATGGGCAAGCCCATCATCCACGTGAGCATGAACCTACCGCGTTGCT
 TCGTGGGGGTTCTTGGCTGGTCCA 540
 M I T A S V L M G K P I I H V S M N Y R V A S W G F L A G P
 GACATCAAGGCCGAGGGCAGCGGGAACGCCGTTTGCACGACCAACGCTTGGGTTTGCAGTGGGT
 GGCGGACAACATTGCCGGGTTCGGC 630
 25 D I K A E G S G N A G L H D Q R L G L Q W V A D N I A G F G
 GGCGACCCGTCCAAGGTGACCATCTTTGGTGAG [REDACTED] GGCGGGCAGCATGTGCGTAATGTGTCAGCT
 CCTCTGGAACGACGGCGACAACACG 720
 G D P S K V T I F G E S A G S M S V M C Q L L W N D G D N T
 TACAACGGCAAGCCGTTGTTCCGTGCCGCCATCATGCAG [REDACTED] GGGGCCATGGTGCCG [REDACTED] GGACCC
 30 GGTGGATGGGCCCTACGGCACGCAG 810
 Y N G K P L F R A A I M Q S G A M V P S D P V D G P Y G T Q
 ATCTACGACCAGGTGGTTGCTTCAGCCGGCTGTGGCAGTGCCAGCGACAAGCTCGCGTGCTTGCG
 CAGCATC [REDACTED] GAACGACAACTCTT 900
 I Y D Q V V A S A G C G S A S D K L A C L R S I S N D K L F
 35 CAGGCCACCAGCGACACTCCGGGGGCCTTGGCGTACCCCTCGTTGCGGTTG [REDACTED] GTTTCTCCCGCGG
 CCCGACGGCACCTTCATCACCGAT 990
 Q A T S D T P G A L A Y P S L R L S F L P R P D G T F I T D
 GACATGTTCAAGTTGGTGCGCGACGGCAAGTGTGCCAACGTTCCGGTGATCATTGGCGACCAGAA
 CGACGAGGGCACAGTGGTTGCGTTG 1080
 40 D M F K L V R D G K C A N V P V I I G D Q N D E G T V F A L

TTGAACGTGACTACGGATGCTCAGGCACGCCAGTACTTCAAGGAA TTCATCCACGC
CAGCGACGCGGAGATCGACACCTTG 1170

S S L N V T T D A Q A R Q Y F K E S F I H A S D A E I D T L

ATGGCGGCGTACCCAGCGACATCACCCAGGGT CCGTTCGACACCGGCATCTTCAACGCCAT
5 CACCCCGCAGTTCAAACGGATTGCA 1260

M A A Y P S D I T Q G S P F D T G I F N A I T P Q F K R I A

GCGGTGCTTGGTGACCTTGCGTTCACTCTCCCCGGCGCTACTTCTCAACCACTTCCAGGGCGGC
ACCAAGTACTCGTTCCTC GAAG 1350

A V L G D L A F T L P R R Y F L N H F Q G G T K Y S F L S K

10 CAGCTT GGGTTGCCGGTGATTGGCACCCACCACGCCAACGACATTGTGTGGCAGGACTTTTTG
GTGAGCCACAGCAGCGCCGTGTAC 1440

Q L S G L P V I G T H H A N D I V W Q D F L V S H S S A V Y

AACAACGCGTTTATTGCCTTTGCCAACGACCTCGACCCGAACAAGGCCGTTTGTGTGAACTGG
CCCAAGTACACCAGCAGC CAG 1530

15 N N A F I A F A N D L D P N K A G L L V N W P K Y T S S S Q

GGCAACAACCTTGTTCAGATCAACGCCTTGGGCTTGTACACCGGCAAGGACAACCTCCGCAC
CGCTGGCTACGACGCGTTGTTTACC 1620

S G N N L L Q I N A L G L Y T G K D N F R T A G Y D A L F T

AACCCG TT TTTGT 1641 (SEQ ID NO:5)

20 N P S S F F V (SEQ ID NO:6)

C. rugosa lipase 5

CGACACCATCACCGGTCTCAACGCC G CCCAC GCCACGCTCGCCAACGG
25 90

S M N S R G P A G R L G S V P T A T L A N G D T I T G L N A

ATCATCAACGAGGCGTTTCTCGGCATTCCCTTTGCCGAGCCGCCGGTGGGCAACCTCCGCTTCAAG
GACCCTGTGCCGTACCGTGGGTCT 180

I I N E A F L G I P F A E P P V G N L R F K D P V P Y R G S

30 CTCAACGGTCAATCCTTACCGGTACGGTCCG TGCATGCAGCAGAACCCCGAGGGCACCTAC
GAGGAGAACCTCCCAAGGTGGCG 270

L N G Q S F T A Y G P S C M Q Q N P E G T Y E E N L P K V A

CTTGACTTGGTGATGCAGTCCAAGGTGTTCCAGGCTGTTCTCCCCAACAGCGAGGACTGCCTCACC
ATCAACGTGGTGCGGCCGCGGGC 360

L D L V M Q S K V F Q A V L P N S E D C L T I N V V R P P G

35 ACCAAGGCGGGCGCCAACCTCCCGTTCATGCTCTGGATCTTTGGCGGTGGGTTTGAGATCGGCAG
CCCCACCATCTTCCCTCCCGTCTAG 450

T K A G A N L P V M L W I F G G G F E I G S P T I F P P A Q

ATGGTCTCCAAGAGTGTGCTCATGGGC AGCCCATCATCCACGTGGCCGTCAACTACCGCTTGGCG
TCCTTTGGTTTCTTGCCGGTCCG 540

40 M V S K S V L M G E P I I H V A V N Y R L A S F G F L A G P

GACATCAAGGCCGAGGGCAGCTCCAATGCCGGCCTCAAGGACCAGCGCTTGGGCATGCAGTGGGT
GGCAGACAACATTGCCGGGTTCGGC 630

D I K A E G S S N A G L K D Q R L G M Q W V A D N I A G F G

5 GGCGACCCGAGCAAGGTGACCATCTTTGGGAGGCGGGCAGCATGTCCGTGTTGTGCCACCTT
CTCTGGAATGGCGGCGACAACACG 720

G D P S K V T I F G E S A G S M S V L C H L L W N G G D N T

TACAAGGGCAAGCCGTTGTTCCGCGCGGGCATCATGCAGGGAGCCATGGTGCCGGACCC
GGTGGACGGCACCTATGGAACCAA 810

Y K G K P L F R A G I M Q S G A M V P S D P V D G T Y G A Q

10 ATCTATGACACGTTGGTGGCTACGGGCTGCAGCAGTGCCAGCAACAAGCTTGCGTGCTTGCCT
GGTCTTACTCAGGCATTGCTC 900

I Y D T L V A S T G C S S A S N K L A C L R G L S T Q A L L

GATGCCACCAACGACACCCCTGGGTTCTTGTCTGACACCTCGTTGCGGTTGTACTCCCGG
CCCGACGGCGCCAACATCACCGAT 990

15 D A T N D T P G F L S Y T S L R L S Y L P R P D G A N I T D

GACATGTACAAGTTGGTACGCGACGGCAAGTATGCAAGCGTTCCCGTGATCATTGGCGACCAGAA
CGACGAGGGCTTCTTGTGTTGTCTC 1080

D M Y K L V R D G K Y A S V P V I I G D Q N D E G F L F D L

20 TTGAACACCACCACCGAGGCCGACGCCGAGGCATACCTCAGAAAGTTCATCCACGCC
ACCGACGCCGATATCACCGCATTG 1170

S S L N T T T E A D A E A Y L R K S F I H A T D A D I T A L

AAGGCGGCGTACCCAGCGATGTCACCCAGGGTCCGTTGACACGGGCATTCTCAACGCCCTT
ACACCCAGCTCAAGCGGATCAAT 1260

K A A Y P S D V T Q G S P F D T G I L N A L T P Q L K R I N

25 GCTGTGCTTGGCGACCTCACCTTTACCCTCTCGCGCCGCTACTTCTCAACCACTACACCGGTGGTC
CCAAGTACTCGTTCCTCAAG 1350

A V L G D L T F T L S R R Y F L N H Y T G G P K Y S F L S K

CAGCTTGGTTGCCATTCTCGGACGTTCCACGCGAACGACATTGTGTGGCAGCACTTTTGT
TGGGCAGCGGCAGCGTCATCTAC 1440

30 Q L S G L P I L G T F H A N D I V W Q H F L L G S G S V I Y

AACAACGCGTTCATCGCGTTTGCCACCGACTTGGACCCCAACACCGCGGGCTTGGTGCAGTGG
CCCAAGTCACCAGCAGCCAG 1530

N N A F I A F A T D L D P N T A G L S V Q W P K Y T S S S Q

35 GCGGGGGACAACCTTGATGCAGATCAGTGCCTTGGGCTTGACACCGCAAGGACAACCTTCCGCAC
CGCCGGCTACAACGCTTTGTTTGCC 1620

A G D N L M Q I S A L G L Y T G K D N F R T A G Y N A L F A

GACCCGCACTTTTTCGTG 1641 (SEQ ID NO:7)

D P S H F F V (SEQ ID NO:8)

C. rugosa lipase 8

[REDACTED]G[REDACTED]CCCAC[REDACTED]GCCACGCTCGCCAACGG
 CGACACCATCACCGGTCTCAACGCC 90
 S M N S R G P A G R L G S V P T A T L A N G D T I T G L N A
 5 ATCATCAACGAGGCGTTCTCGGCATTCCCTTTGCCGAGCCGCCGGTGGGCAACCTCCGCTTCAAG
 GACCCCGTGCCGTACTCCGGCTCG 180
 I I N E A F L G I P F A E P P V G N L R F K D P V P Y S G S
 CTCGATGGCCAGAAGTTTAC[REDACTED]TACGGCCCG[REDACTED]TGCATGCAGCAGAACCCCGAGGGCACCTAC
 GAGGAGAACCTCCCCAAGGCAGCG 270
 10 L D G Q K F T S Y G P S C M Q Q N P E G T Y E E N L P K A A
 CTCGACTTGGTGTATGCAGTCCAAGGTGTTTGAAGCGGTG[REDACTED]CCG[REDACTED]AGCGAGGACTGTCTCACC
 ATCAACGTGGTGCAGCGCCGCCGGG 360
 L D L V M Q S K V F E A V S P S S E D C L T I N V V R P P G
 ACCAAGGCGGGTGCCAACCTCCCGGTGATGCTCTGGATCTTTGGCGGGCGGGTTTGAAGTGGGTGG
 15 CACCAGCACCTTCCCTCCCGCCAG 450
 T K A G A N L P V M L W I F G G G F E V G G T S T F P P A Q
 ATGATCACCAAGAGCATTGCCATGGGCAAGCCCATCATCCACGTGAGCGTCAACTACCGCGTGTG
 GTCGTGGGGGTTCTTGGCTGGCGAG 540
 M I T K S I A M G K P I I H V S V N Y R V S S W G F L A G D
 20 GAGATCAAGGCCGAGGGCAGTGCCAACGCCGTTTGAAGGACCAGCGC[REDACTED]TGGGCATGCAGTGGG
 TGGCGGACAACATTGCGGCGTTTGGC 630
 E I K A E G S A N A G L K D Q R M G M Q W V A D N I A A F G
 GGCGACCCGACCAAGGTGACCATCTTTGGCGAG[REDACTED]GCGGGCAGCATGTGCGTCATGTGCCACAT
 TCTCTGGAACGACGGCGACAACAG 720
 25 G D P T K V T I F G E S A G S M S V M C H I L W N D G D N T
 TACAAGGGCAAGCCGCTCTTCCGCGCGGGCATCATGCAG[REDACTED]GGGGCCATGGT[REDACTED]CCG[REDACTED]GGACGC
 [REDACTED]GTGGACGGC[REDACTED]TCTACGGCAACGAG 810
 Y K G K P L F R A G I M Q S G A M V P S D A V D G V Y G N E
 ATCTTTGACCTCTTGGCGTCG[REDACTED]ACGCGGGCTGCGGCAGCGCCAGCGACAAGCTTGCCTGCTTGGCG
 30 GGTGTG[REDACTED]AGCGACACGTTGGAG 900
 I F D L L A S D A G C G S A S D K L A C L R G V S S D T L E
 GACGCCACCAACAACACCCCTGGGTTCTTGGCGTACTCCTCGTTGCGGTTG[REDACTED]TA[REDACTED]CTCCC[REDACTED]CGG
 CCCGACGGCGTGAACATCACCGAC 990
 D A T N N T P G F L A Y S S L R L S Y L P R P D G V N I T D
 35 GACATGT[REDACTED]GCCTTGGT[REDACTED]CGCGAGGGCAAGTATGC[REDACTED]A[REDACTED]C[REDACTED]T[REDACTED]CCTGTGATCATCGGCGACCAGAA
 CGACGAGGGCACCTTCTTTGGCACC 1080
 D M F A L V R E G K Y A S V P V I I G D Q N D E G T F F G T
 [REDACTED]TTGAACGTGACCACGGATGCC[REDACTED]AGGCCCGC[REDACTED]AGTACTTCA[REDACTED]GCAG[REDACTED]TTTGTCCACGCC
 AGCGACGCGGAG[REDACTED]TCGACACGTTG 1170
 40 S S L N V T T D A E A R Q Y F T Q S F V H A S D A E L D T L

ATGACGGCGTACCCG GACATCACCCAGGG CCGTTCGACACGGGT TTCTCAACGCCCTC
ACCCCGCAGTTCAAGAGAATC 1260

M T A Y P Q D I T Q G S P F D T G V L N A L T P Q F K R I S

GCGGTGCTCGGCGACCTTG CTT A C GC CGTCGCTACTTCCTCAACCACTACACCGGCGGC
5 ACCAAGTACTCATTCTC AAG 1350

A V L G D L A F I H A R R Y F L N H Y T G G T K Y S F L S K

CAGCTC GGCTTGCCGGTGCTCGGAACGTTCCACTCCAACGACATTGTCTTCCAGGACTACTTG
TTGGGCAGCGGCTCGCTCATCTAC 1440

Q L S G L P V L G T F H S N D I V F Q D Y L L G S G S L I Y

10 AACACGCGTTTATTGCGTTTGCCACGGACTTGACCCCAACACCGCGGGGTTGTTGGTGAAGTG
GCCCCGAGTACACCAGCAGC CAG 1530

N N A F I A F A T D L D P N T A G L L V K W P E Y T S S S Q

GGCAACAACCTTGATGATGATCAACGCCTTGGGCTTGTACACCGGCAAGGACAACCT CCGCAC
CGCCGGCTACGACGCGTTGTTCTCC 1620

15 S G N N L M M I N A L G L Y T G K D N S R T A G Y D A L F S

AACCCGCCG TTCTTTGTG 1641 (SEQ ID NO:9)

N P P S F F V (SEQ ID NO:10)

The differences between each mutant DNA and its corresponding wild-type DNA are
due to replacement of the CTG codons with the universal serine codons, and in addition, can
be due to degeneracy of genetic codons, which results in a DNA variant encoding, based on
universal codons, a wild type *C. rugosa* lipase or a functionally equivalent amino acid
sequence thereof. An isolated nucleic acid containing such a mutant DNA can be used to
clone and express the *C. rugosa* lipase in a common host cell. A DNA variant can possess
the codons preferred by a particular prokaryotic or eukaryotic host. The codons may be
selected to increase the rate at which expression of a polypeptide occurs in the prokaryotic or
eukaryotic host in accordance with the frequency with which the codons are utilized by the
host. The mutant DNA can further include such variations as nucleotide substitutions,
deletions, inversions, or insertions on the wild-type DNA. The variations can modify the
cloning, processing, and expression of the *C. rugosa* lipase.

The just-described mutant DNA can be prepared based on site-directed mutagenesis,
introducing very specific nucleotide substitutions (i.e., mutations) at defined locations in a
nucleic acid sequence. See, for example, Zoller and Smith (1983) *Meth. Enzymol.* 100: 468;
and *Molecular Cloning, A Laboratory Manual* (1989) Sambrook, Fritsch and Maniatis, Cold
Spring Harbor, N.Y., chapter 15. Alternatively, the mutant DNA may be synthesized, in
whole or in part, using chemical methods well known in the art. See Caruthers *et al.* (1980)

Nucl. Acids Res. Symp. Ser. 215-223, and Horn *et al.* (1980) *Nucl. Acids Res. Symp. Ser.* 225-232. In particular, introducing multiple mutations can be accomplished through various methods based on, e.g., polymerase chain reaction (PCR), ligase chain reaction (LCR), or overlap extension polymerase chain reaction. See Ge and Rudolph (1997) *BioTechniques* 22: 28-30.

The mutant DNA can encode a polypeptide of SEQ ID NO:2, 4, 6, 8, or 10. Alternatively, it can encode a polypeptide variant having an amino acid sequence that is 90% identical to, or differs by 1, 5, 10, 50, or more amino acid residues from, SEQ ID NO:2, 4, 6, 8, or 10. If alignment is needed for this comparison, the sequences should be aligned for maximum homology. The polypeptide variant is correlated with at least one catalytic activity of a polypeptide encoded by SEQ ID NO:2, 4, 6, 8, or 10, e.g., ester bond hydrolysis or esterification. A polypeptide variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In some embodiments, a polypeptide variant may have "nonconservative" changes, e.g., replacement of a leucine with a methionine. Further, a polypeptide variant may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing the catalytic activity may be found using computer programs well known in the art, for example, DNASTAR software.

It is well known that cutinase is the smallest lipolytic enzyme with determined three-dimensional structure, and may be considered an esterase with a broader activity that also includes lipids. Based on the alignment of secondary structure (e.g., α -helix or β -strand), topology of the *C. rugosa* lipase polypeptide chain is similar to that of cutinase (the three dimensional structures of LIP1 and LIP3 have been determined. See, for example, Grochulski *et al.* (1993) *J. Biol. Chem.* 268: 12843-12847; and Ghosh *et al.* (1995) *Structure* 3: 279-288). Therefore, according to the common folding pattern of lipase (Cygler *et al.* (1997) *Methods in*

Enzymol 284: 3-37), the minimal functional fragment of *C. rugosa* lipase within the range of residues 100-456 can be determined (e.g., the β 2 strand to α 8,9 helix, totally about 350 amino acids and 1070 nucleotides).

The polypeptide having the amino acid sequence of SEQ ID NO:2 differs from the wild-type *C. rugosa* lipase 2 a N-terminal peptide (i.e., SMNSRGPAGRLGS), and 4 amino acids (i.e., A1V; T35S; R78L; H79D). The polypeptide having the amino acid sequence of SEQ ID NO:4 differs from the wild-type *C. rugosa* lipase 3 by the N-terminal peptide and 5 amino acids (i.e., A1V; P148H; I395V; F396L; I399L). The polypeptide having the amino acid sequence of SEQ ID NO:6 differs from the wild-type *C. rugosa* lipase 4 by the N-terminal peptide and 1 amino acid (i.e., A1V). The polypeptide having the amino acid sequence of SEQ ID NO:8 differs from the wild-type *C. rugosa* lipase 5 by the N-terminal peptide and 5 amino acids (i.e., A1V; K147E; T256A; G346D; S492Y). The polypeptide having the amino acid sequence of SEQ ID NO:10 differs from the wild-type *C. rugosa* lipase 1 by the N-terminal peptide and 17 amino acids (i.e., A1V; L184M; I253V; N265D; Y320F; N330S; I331V; Q357E; E360Q; K363T; I374L; G383Q; I395V; G414A; T416I; L417H; F517S).

The just-described polypeptide can be produced by using an expression vector that contains an isolated nucleic acid of this invention. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. A vector is capable of autonomous replication, and contains the nucleic acid of this invention in a form suitable for expression of the nucleic acid in a host cell. It includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term “regulatory sequence” includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory or inducible sequences. A vector can be designed for expression of a *C. rugosa* lipase in prokaryotic or eukaryotic cells, e.g., bacterial cells (e.g., *E. coli*), insect cells (e.g., using baculovirus expression vectors), yeast cells (e.g., *P. pastoris*), or mammalian cells. Suitable host cells are discussed further in Goeddel, (1990) *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA. Expression of a *C. rugosa* lipase can be carried out with vectors

containing constitutive or inducible promoters directing the expression of either fusion or non-fusion lipases. The fusion lipase may facilitate purification of soluble polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the polypeptide. Typical fusion expression vectors include pGEX

5 (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA), and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target polypeptide.

A vector can be introduced into host cells via conventional transformation or

10 transfection techniques. As used herein, the terms “transformation” and “transfection” refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. A host cell of the invention can be used to express a *C. rugosa* lipase. The expressed *C. rugosa* lipase can be isolated from the

15 host cell or a culture medium.

The present invention also provides a chimeric *C. rugosa* lipase that contains a substrate interacting domain of an isozyme and a non-substrate interacting domain of another isozyme. The “substrate interacting domain” refers to a fragment that is characterized by an approximated 32 amino acid sequence (e.g., amino acids of 63-94 of SEQ ID NO:8), and

20 participates in substrate interactions. The “non-substrate interacting domains” include at least one catalytic domain, such as a carboxylesterase domain. The substrate interacting domain can be a part of the substrate binding region, which is generally dispersed along the full length amino acid sequence, and forms a tunnel to interact with, e.g., fatty acyl chain. See Cygler *et al.* (1999) *Biochim. Biophys. Acta* 1441: 205-214.

25 The carboxylesterase domain can catalyze hydrolysis of carboxylic esters, and include a catalytic triad: a serine, a glutamate (or aspartate), and a histidine. The sequence around the active site serine is well conserved and can be used as a signature pattern. See, e.g., Krejci *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88: 6647-6651(1991), or Cygler *et al.* (1993) *Protein Sci.* 2: 366-382. The chimeric polypeptide of this invention can be prepared

30 by a domain shuffling method. For example, the method includes exchanging the SphI(184)-BstXI(304) restriction DNA fragments to obtain a recombinant nucleic acid encoding a

5 mature chimeric *C. rugosa* lipase. The mature lipase contains a substrate interacting domain of an isozyme and non-substrate interacting sequences of another isozyme (e.g., LIP4). The recombinant nucleic acid is then ligated into a vector, e.g., pET-23a(+) *E. Coli*. T7 expression vector (Novagen) between *Nde* I and *Eco*RI sites.

Each of the just-described domains has at least 70% (e.g., 80%, 90%, 95%, or 100%) homology with its corresponding wild-type sequence, as long as its intended function in the chimeric polypeptide is retained. The chimeric polypeptide can be produced as a fusion chimeric polypeptide, e.g., a thioredoxin fused to the N-terminal of a chimeric polypeptide.

10 The specific example below is to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications cited herein are hereby incorporated by reference in their entirety.

15 Expression of *C. rugosa* lipase 2 (LIP2)

Materials and Methods

Strains and plasmids Plasmid-containing transformants were mainly grown in Luria-Bertani (LB) broth supplemented with ampicillin (100 µg/mL). The *P. pastoris* expression vector pGAPZα C (Invitrogen, Carlsbad, CA) was manipulated in *E. coli* strain TOP 10' grown in low salt Luria-Bertani (LB) broth (1% tryptone, 0.5% yeast extract, and 0.5% NaCl, pH 7.5) supplemented with zeocin (25 µg/mL). *P. pastoris* X-33 (wild type) was used for the expression of *LIP2*, and its transformants were cultured with YPD (0.1% yeast extract, 0.2% peptone, and 0.2% dextrose; pH 7.2) containing 100 µg/mL zeocin at 26°C.

25 *Construction of expression vector.* *LIP2* has been sequenced previously (EMBL Databank accession number X64704). A PCR product containing the entire *LIP2* coding region with a *Kpn* I restriction site at the 5' end and *Not* I site at the 3' end was prepared and cloned into the *Kpn* I – *Not* I sites of the *P. pastoris* expression vector pGAPZα C to generate pGAPZα-*LIP2*.

30 *Transformation of plasmid DNAs into *P. pastoris*.* Plasmid DNA (10 µg) harboring the engineered lipase gene was digested with *Eco*RV in a total volume of 20 µL for 2 h. Linearized plasmid was transformed into *P. pastoris* by the electroporation method. High

voltage pulses (1.5 kV) were delivered to 100 μ L samples in 0.2 cm electrode gap cuvettes (Bio-Rad Laboratories) by using a Gene Pulser[®] apparatus with the Pulse Controller (Bio-Rad Laboratories). Individual colonies of transformants were pitched and patched on tributyrin-emulsion YPD plates. The lipase-secreting transformants were identified by the clear zone on the opaque tributyrin emulsion. *P. pastoris* transformed with pGAPZ α C was used as a negative control.

Purification of recombinant LIP2. The culture medium from *P. pastoris* was concentrated by ultrafiltration on a 30,000 molecular weight cut-off membrane. These samples were then applied onto a HiPrep[™] 16/10 Octyl FF column (Pharmacia Biotech). The column was washed with 5 column volumes of TE buffer plus 1 mM CHAPS and then 4 mM CHAPS. Bound proteins were then eluted with 5 column volumes of TE buffer containing 30 mM CHAPS. The eluted materials were dialyzed against TE buffer.

The eluted proteins were then applied to a HiPrep[™] 16/10 Q XL column (Pharmacia Biotech) equilibrated with TE buffer and the proteins were eluted using a linear gradient of 0 to 300 mM (NH₄)₂SO₄ over 5 column volumes. Protein concentrations in the fractions were measured with the Bio-Rad assay kit and esterase activity was determined using *p*-nitrophenyl butyrate as a substrate. Purified proteins were stored in a storage buffer (60 mM KCl, 10 mM Tris-HCl, 1.25 mM EDTA, 1% Triton X-100, and 17% glycerol, pH 7.5) at -20°C.

Enzyme characterization. The molecular masses of the purified recombinant *LIP2* and a commercial lipase (Lipase Type VII, Sigma) were determined by SDS-PAGE analysis. To analyze the thermal stability of lipase, samples were incubated at various temperatures from 37 to 100°C for 10 minutes, and the residual activities were determined by spectrophotometric method (Redondo *et al.* (1995) *Biochim. Biophys. Acta* 1243 :15-24), using *p*-nitrophenyl caprylate as a substrate at 37°C. The optimal reaction temperature for lipase was investigated at different temperatures from 10 to 60°C, and the activity was measured by spectrophotometric method using *p*-nitrophenyl butyrate as a substrate at pH 7.0. The optimal reaction pH for lipase was investigated at different pH from 3.0 to 9.0, and the activity was measured by spectrophotometric method using *p*-nitrophenyl butyrate as a substrate at 37°C.

The lipase activities were measured by titrimetry using triglycerides with various chain-length fatty acids as substrates. See Wang *et al.* (1988) *Biotechnol. Bioeng.* 31: 628-633. The release of free fatty acid was continuously monitored by titration with 1 mM NaOH on the pH-Stat. The esterase activity at 37°C was determined spectrophotometrically using *p*-nitrophenyl esters as substrates. One unit of activity was defined as the smallest amount of enzyme able to release 1 μ mol of *p*-nitrophenol per minute.

Results

Construction of Expression Plasmids and Overexpression of Recombinant LIP2 All 17 CTG codons of *LIP2* gene were replaced with universal Ser codons (TCT) by simultaneous multiple site-directed mutagenesis. See Ge and Rudolph (1997) *BioTechniques*. 22: 28-30. The plasmid harboring the engineered *LIP2* was transformed into *P. pastoris* by electroporation. The transformant cells were grown in 500-mL flasks containing 200 mL YPD medium for three days. The constitutive strong promoter of glyceraldehydes 3-phosphate dehydrogenase (GAP) allows the high level expression of *LIP2*. The majority of expressed *LIP2* was secreted into the culture medium and the estimated amount of *LIP2* was 2.3 mg/L. The transformants are highly stable and the produced *LIP2* would be greatly increased in high cell density fermentation. See Cereghino and Cregg (2000) *FEMS Microbiol. Rev.* 24: 45-66.

Biochemical characterization of recombinant LIP2 The optimal pH of *LIP2* was 7 and the enzyme showed 90% of activity at pH 6. In contrast, the optimal pHs of *LIP4* and a commercial *C. rugosa* lipase (CRL) were pH 7-8 and 8, respectively. *LIP2* showed much higher specific activity than *LIP4* and CRL with *p*-nitrophenyl butyrate at all pH tested, especially at pH 6. The ratio of specific activity of *LIP2*, *LIP4* and CRL was 100:4:3 at pH 6, whereas it was 100:80:25 at pH 8. Therefore, the *LIP2* is especially useful at slightly acidic to neutral pH for industrial applications.

Further, the optimal temperatures for *LIP2*, *LIP4* and CRL were 40-50, 40 and 37°C, respectively. The *LIP2* showed broad optimum temperature range 30-50°C and much higher specific activity than *LIP4* and CRL at all temperature tested (10-60°C). Unexpectedly, *LIP2* showed quite high activity at low temperature, e.g., the specific activity at 10°C was 1000 U/mg, which was 50% of that at optimum temperature. This suggested that the enzyme

could be applied to the synthesis of labile compounds and low boiling point compounds at low temperature.

The enzyme activities after heating at various temperatures for 10 min were also compared. The LIP2 was more stable than either LIP4 or CRL at 50-70°C. After 10 min heating at 70°C, the residual activities for LIP2, LIP4 and CRL were 80%, 50% and 35%, respectively.

For the hydrolysis of p-nitrophenyl esters of various chain-length fatty acids (Table 1), LIP2, LIP4 and CRL showed different preference to ester substrates. The best substrates for LIP2, LIP4 and CRL were p-nitrophenyl palmitate, p-nitrophenyl palmitate and p-nitrophenyl caprylate, respectively. Both LIP2 and LIP4 showed much higher activity toward medium to long chain fatty acid esters (C₁₂-C₁₈), but LIP2 had 2-3 times higher activity than LIP4. For most the p-nitrophenyl esters including p-nitrophenyl butyrate, -caprylate, -caprate, -laurate, -myristate, -palmitate and -stearate, the specific activities were in the order: LIP2> LIP4> CRL.

Hydrolysis activities of triglycerides One important industrial application of lipases is the hydrolysis of fat and vegetable oils, which occur naturally as triglycerides, to produce fatty acids. See, e.g., Shaw *et al.* (1990) *Biotechnol. Bioeng.* 35: 132-137. Table 2 showed LIP2, LIP4 and CRL had different preference to triglyceride substrates. The best triglyceride substrates for LIP2, LIP4 and CRL were tributyrin, tricaprylin and tricaprylin, respectively.

For tributyrin, trilaurin, tripalmitin, tristearin and triolein, the specific activity of hydrolysis was in the following order: LIP2> LIP4> CRL. For triacetin and tricaproin, the order was LIP2> CRL> LIP4. For tricaprylin, the order was: LIP4> CRL> LIP2. For tricaprinn and trimyrustin, the order was: CRL> LIP2> LIP4. Therefore, different LIP isoforms should be used for different industrial applications in triglyceride hydrolysis.

Cholesterol esterase activity As shown in Table 3, LIP2 showed much higher specific activity of cholesterol esterase than LIP4 and CRL among three cholesteryl esters tested. Among various cholesteryl esters, cholesteryl laurate was the best substrate hydrolyzed by LIP2. Therefore, the LIP2 can be used as a useful cholesterol esterase for the applications in clinical chemistry, biochemistry and food analysis. Since about 70-80% of serum cholesterol is esterified with various chain-length and saturated fatty acids (Röschlau *et al.* (1974) 12: 403-407), therefore LIP2, which has cholesterol esterase activity, can be

used for coupling with cholesterol oxidase and peroxidase to determine the serum cholesterol enzymatically. The high specific activity of LIP2 toward the various cholesteryl esters allows very efficient and accurate determination of the cholesterol esters in serum and food.

Synthesis of esters Lipase can efficiently catalyze the synthesis of various esters for industrial applications such as fruit-flavored products (e.g. beverages, candies, jellies, and jams), baked goods, wines, dairy products (e.g. cultured butter, sour cream, yogurt, and cheese), emulsifiers, lubricants and cosmetics. See, for example, Kim *et al.* (1998) *J. Am. Oil Chem. Soc.* 75: 1109-1113; Shaw and Lo (1994) *J. Am. Oil Chem. Soc.* 71: 715-719; or Shaw *et al.* (1991) *Enzyme Microb. Technol.* 13: 544-546. Table 4 showed that LIP2 was much better than either LIP4 or CRL in the synthesis of hexadecyl or octadecyl myristate, suggesting it favored long-chain alcohols in the esterification of myristic acid with equimolar mixtures of different alcohols. In contrast, CRL was the best for the synthesis of hexyl-, octyl- and dodecyl- myristate, suggesting it favored medium to short chain alcohols for myristic ester synthesis.

Table 5 showed that LIP2 had much higher activity for the synthesis of propyl butyrate than either LIP4 or CRL, suggesting it favored short chain acids in the esterification of n-propanol with equimolar mixtures of different chain length fatty acids. In contrast, LIP4 was the best for the synthesis of propyl dodecanoate, hexadecanoate and octadecanoate, suggesting it favored medium to long chain fatty acids for propyl ester synthesis.

Table 1. Hydrolysis of *p*-nitrophenyl (*p*-NP) esters of various chain-length fatty acids.

	LIP2	LIP4	CRL
	(U/mg ^a)		
<i>p</i> -NP acetate (C2)	11 ± 1 (0.4) ^b	10 ± 1 (0.7)	16 ± 2 (3.1)
<i>p</i> -NP butyrate (C4)	1986 ± 30 (72)	899 ± 20 (63)	359 ± 42 (72)
<i>p</i> -NP caproate (C6)	108 ± 15 (4)	151 ± 13 (11)	72 ± 5 (14)
<i>p</i> -NP caprylate (C8)	978 ± 126 (35)	504 ± 24 (35)	498 ± 67 (100)
<i>p</i> -NP caprate (C10)	1453 ± 210 (53)	1295 ± 179 (91)	395 ± 19 (79)
<i>p</i> -NP laurate (C12)	2567 ± 277 (93)	867 ± 41 (61)	269 ± 44 (54)
<i>p</i> -NP myristate (C14)	2567 ± 277 (93)	1140 ± 41 (80)	372 ± 5 (75)
<i>p</i> -NP palmitate (C16)	2766 ± 4 (100)	1429 ± 127 (100)	317 ± 5 (64)
<i>p</i> -NP stearate (C18)	1580 ± 21 (57)	580 ± 21 (41)	67 ± 1 (13)

a. The unit (U) definition: One unit of activity is the amount of enzyme necessary to hydrolyze 1.0 micromole of *p*-nitrophenyl ester per min at 37°C and pH 7.0.

b. The parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

Table 2. Hydrolysis of triglyceride of various chain-length fatty acids.

	LIP2	LIP4	CRL
	(U/mg ^a)		
Triacetin (C2)	39 ± 1 (2) ^b	10 ± 1 (0)	11 ± 1 (0)
Tributylin (C4)	2540 ± 60 (100)	1138 ± 10 (28)	1029 ± 64 (33)
Tricaproin (C6)	599 ± 37 (24)	167 ± 7 (4)	358 ± 14 (11)
Tricaprylin (C8)	1239 ± 31 (49)	4082 ± 298 (100)	3118 ± 190 (100)
Tricaprin (C10)	1399 ± 17 6 (55)	628 ± 11 (15)	2160 ± 75 (69)
Trilaurin (C12)	1743 ± 11 0 (69)	389 ± 4 (10)	1502 ± 8 (48)
Trimyristin (C14)	504 ± 33 (20)	375 ± 33 (9)	915 ± 26 (29)
Tripalmitin (C16)	54 ± 6 (2)	151 ± 10 (4)	137 ± 12 (4)
Tristearin (C18)	422 ± 9 (17)	348 ± 38 (9)	39 ± 2 (1)
Triolein (C18:1)	513 ± 4 (20)	352 ± 5 (9)	303 ± 24 (10)

- a. The unit (U) definition: One unit of activity is the amount of enzyme necessary to hydrolyze 1.0 micromole of ester bond per min at 37°C and pH 7.0.
- b. The parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

5

10

Table 3. Hydrolysis of cholesterol esters of various chain-length fatty acids.

	LIP2	LIP4	CRL
	(10 ⁻² U/mg ^a)		
Cholesteryl n-butyrate (C4)	127.1 ± 1.4 (32) ^b	24.7 ± 1.3 (25)	7.3 ± 0.1 (53)
Cholesteryl laurate (C12)	402.0 ± 35.5 (100)	98.2 ± 3.2 (100)	13.8 ± 0.5 (100)
Cholesteryl stearate (C18)	127.1 ± 1.4 (32)	45.0 ± 1.8 (46)	6.5 ± 0.7 (47)

- a. The unit (U) definition: One unit of activity is the amount of enzyme necessary to hydrolyze 1.0 micromole of cholesteryl ester per min at 37°C and pH 7.0.
- b. The parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

Table 4. Esterification of myristic acid with various chain-length alcohols.

	LIP2	LIP4	CRL
	$(10^3 \mu\text{mol/h/mg})^a$		
n-hexyl myristate	1.86±0.17 (57) ^b	2.35±0.24 (100)	3.89±0.47 (100)
n-octyl myristate	2.28±0.27 (70)	1.55±0.16 (66)	2.73±0.30 (70)
n-dodecyl myristate	1.16±0.11 (35)	0.66±0.07 (28)	1.79±0.20 (46)
n-hexadecyl myristate	2.33±0.22 (72)	1.04±0.08 (44)	1.13±0.13 (29)
n-octadecyl myristate	3.26±0.33 (100)	1.71±0.11 (72)	1.19±0.07 (31)

a. Initial rate of reaction in the esterification of myristic acid with equimolar mixtures of different chain-length alkyl alcohols catalyzed by recombinant and a commercial CRLs.

b. The parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

Table 5. Esterification of various chain-length acids with n-propanol.

	LIP2	LIP4	CRL
		(10 ³ μmol/h/mg) ^a	
n-propyl butyrate	9.96±1.04 (100) ^b	5.19±0.49 (100)	0.95±0.05 (99)
n-propyl octanoate	2.41±0.24 (24)	2.35±0.11 (45)	0.68±0.05 (70)
n-propyl dodecanoate	1.10±0.13 (11)	1.35±0.06 (26)	0.43±0.05 (45)
n-propyl hexadecanoate	0.68±0.07 (7)	1.56±0.21 (30)	0.96±0.12 (100)
n-propyl octadecanoate	0.77±0.02 (8)	1.01±0.06 (19)	0.94±0.12 (98)

a. Initial rate of reaction in the esterification of n-propanol with equimolar mixtures of various chain-length fatty acids catalyzed by recombinant and commercial CRLs.

b. The parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

Expression of chimeric proteins

Material and Methods

Construction of expression vectors The *E. coli* expression vectors pET23a-LIP4-S19 and pET23a-trx-LIP4-S19 were constructed as described in Tang *et al.* (2000) *Protein Exp. Purif.* 20: 308-313. Open-reading frames of *LIP1*, *LIP2*, *LIP3*, and *LIP5* without the leader sequence were obtained by reverse transcription-polymerase chain reaction (RT-PCR). See Longhi *et al.* (1992) *Biochim. Biophys. Acta* 1131:227-232; and Lotti *et al.* (1993) *Gene* 124:44-55. The chimeric DNA sequences were constructed by replacing the SphI(184)-BstXI(304) restriction DNA fragment of *LIP4* with the corresponding fragments of *LIP1*, *LIP2*, *LIP3*, or *LIP5*, respectively. The resulting sequences encode mature chimeric *C. rugosa* lipases, denoted as TrX-LIP4/lid1, TrX-LIP4/lid2, TrX-LIP4/lid3, and TrX-LIP4/lid5, and were confirmed by DNA sequencing.

Preparation of recombinant LIP4 from E. coli. *E. coli* strain AD494(DE3) (Novagen, Milwaukee, WI) harboring recombinant plasmid was grown overnight at 37°C in Luria-Bertani (LB) broth supplemented with 50 µg/mL ampicillin and 15 µg/mL kanamycin. The cells were then diluted 20-fold into fresh medium and incubated with shaking at 25°C. After adding IPTG to give a final concentration of 0.05 mM, the cells were incubated at 10°C until OD₆₀₀ reached 1.0.

Purification of recombinant LIP4. After induction, the AD494(DE3) transformants were harvested by centrifugation at 4000g and 4°C for 10 min. The cell pellet was resuspended in TE buffer (20 mM Tris-HCl and 2.5 mM EDTA, pH 8.0). The cells were disrupted with a sonicator, and the soluble fractions of the cell lysates were then collected by centrifugation at 15,000g at 4°C for 30 min. The soluble fractions were concentrated by ultrafiltration on a 10,000 molecular weight cut-off membrane. These samples were then applied onto a DEAE-Sepharose CL-6B (Pharmacia Biotech) column equilibrated with TE buffer. Recombinant lipases were eluted using a linear gradient of 0 to 100 mM (NH₄)₂SO₄ over 5 column volumes.

The eluted proteins were then applied to a Butyl-Sepharose 4 Fast Flow (Pharmacia Biotech) hydrophobic interaction column. The column was washed with 5 bed volumes of TE buffer plus 1 mM and then 4 mM CHAPS. Bound proteins were then eluted with 5 bed volumes of TE buffer containing 30 mM CHAPS. The eluted samples were dialyzed against

TE buffer and stored in a storage buffer (60 mM KCl, 10 mM Tris-HCl, 1.25 mM EDTA, 1% Triton X-100, and 17% glycerol, pH 7.5) at -20°C. Protein concentrations in the fractions were measured with the Bio-Rad assay kit, and esterase activity was determined using *p*-nitrophenyl butyrate as a substrate. The molecular masses of the purified recombinant lipases and a commercial lipase (Lipase Type VII, Sigma L1754) were determined by SDS-PAGE analysis.

Chimeric protein expression. A chimeric protein, its substrate interacting domain exchanged with one of another isomer, was prepared as described above.

Enzyme assay. Lipase activities were measured by titrimetry using tributyrin as substrates. The release of free fatty acid was continuously monitored by titration with 10 mM NaOH on the pH-Stat. The esterase activity at 37°C was determined spectrophotometrically using *p*-nitrophenyl esters as substrates. One unit of activity was defined as the amount of enzyme that is able to release 1 µmol of *p*-nitrophenol per minute.

Results

To improve the protein solubility and facilitate the purification, the *E. coli* thioredoxin (Trx) was fused to the N-terminal of LIP4 to produce fusion protein Trx-LIP4. The Trx-LIP4 had better solubility and retained activity similar to native LIP4. Although the pairwise identities of overall amino acid sequence of LIP1, LIP2, LIP3 and LIP5, compared with LIP4, were 81, 83, 84 and 78%, respectively, but the substrate interacting domain (i.e., lid region) amino acid identities were 50, 53, 50 and 56% (Table 6), respectively.

To study the effect of the lid region on lipase activity and specificity, lid regions from the other four *C. rugosa* isoforms (LIP1, 2, 3, and 5; and corresponding lids 1, 2, 3, and 5) were exchanged with that of LIP4 and expressed as chimeric proteins Trx-LIP4/lid1, Trx-LIP4/lid2, Trx-LIP4/lid3 and Trx-LIP4/lid5, respectively. As shown in Table 7, the lipase hydrolysis activities of Trx-LIP4/lid2 and Trx-LIP4/lid3 increased 14% and 32%, respectively, whereas Trx-LIP4/lid1 and Trx-LIP4/lid5 decreased 85% and 20%, respectively, compared with native LIP4 with tributyrin as a substrate.

The effect of lid on lipase specificity depended greatly on which substrate was used. As shown in Table 8, although all the chimeric proteins with lid changes showed decreases in activity to varying extents, compared with native Trx-LIP4, the relative activities for various cholesterol esters of different chain length fatty acids showed substantial changes. For

example, the best substrate for Trx-LIP4, Trx-LIP4/lid2 and Trx-LIP4/lid3 is cholesterol caprate, but the best for Trx-LIP4/lid1 and Trx-LIP4/lid5 is cholesterol stearate. In contrast, when *p*-nitrophenyl esters were used as substrates, both *p*-nitrophenyl caprate and stearate were the best substrates for Trx-LIP4 and Trx-LIP2, whereas only *p*-nitrophenyl caprate was the best substrate for Trx-LIP4/lid1, Trx-LIP4/lid3 and Trx-LIP4/lid5. The lid change also affected the substrate specificity of enzymes on the selectivity of cholesterol esters of various desaturated fatty acids. As shown in Table 9, the cholesteryl oleate (18:1) was the best substrate for Trx-LIP4, followed by cholesteryl linoleate (18:2, relative activity 68%), whereas cholesteryl stearate (18:0) was a poor substrate (relative activity 7%). Trx-LIP4/lid2 and Trx-LIP4/lid3 had a similar substrate preference pattern.

Further, the best substrate for Trx-LIP4/lid1 was cholesteryl stearate, followed by cholesteryl linoleate and then cholesteryl oleate. For Trx-LIP4/lid5, the substrate preference order was cholesteryl oleate, cholesteryl stearate, and cholesteryl linoleate. The kinetic parameters of various recombinant LIP4 chimeric proteins with cholesteryl linoleate were analyzed. As shown in Table 10, the fusion protein Trx-LIP4 showed a *k*_{cat}/*K*_m similar to native LIP4 although both *V*_{max} and *K*_m were increased. Trx-LIP4/lid2 retained a catalytic efficiency similar to Trx-LIP4, whereas Trx-LIP4/lid1, Trx-LIP4/lid3 and Trx-LIP4/lid5 showed greatly decreased *k*_{cat}/*K*_m. The decrease in the catalytic efficiency appeared due to the great decrease in *k*_{cat}.

The lid domain also affected the enantioselectivity of lipase. As shown in Table 11, the *C. rugosa* lipase favored the hydrolysis of *l*-menthyl acetate over *d*-menthyl acetate. The recombinant Trx-LIP4 and all the chimeric LIP4 showed much better enantioselectivities than a commercial *C. rugosa* lipase (Lipase Type VII, Sigma). Only the enantioselectivity of Trx-LIP4/lid3 was similar to Trx-LIP4. Other chimeric proteins (Trx-LIP4/lid1, Trx-LIP4/lid2 and Trx-LIP4/lid5) showed substantial decreases in enantioselectivity with methyl acetate as a substrate. The enantioselectivity preference order might quite possibly change if other chiral substrates were used.

What is the structural basis of the lid domain effect on lipase catalysis? From computer analysis, positively charged Lys75 in the lid domain of native LIP4 (lid4) formed a hydrogen bonding and an electrostatic interaction with negatively charged Asp292, residing on the protein surface, to stabilize the lid4 in the open form conformation (an active state of

lipase for hydrophobic substrates). Therefore this contributed to the high activity of LIP4 toward hydrophobic substrates such as medium and long chain fatty acid esters (Table 8-10). The lid2 domain has a lid conformation and amino acid residues similar to the lid4 in stabilizing the open form conformation (Table 6), and therefore the Trx-LIP4/lid2 chimeric protein showed a catalytic efficiency close to that of Trx-LIP4. In contrast, the Lys75-Asp292 interactions were disturbed by Glu71 in lid1, 3, and 5, and therefore these chimeric proteins showed great decreases in catalytic efficiency for hydrophobic substrates.

For short chain hydrophilic substrates, the effect of this open form stabilization is less important. Thus, the even better lipase activity of Trx-LIP4/lid3 for tributyrin hydrolysis than Trx-LIP4 (Table 7) might be due to the different conformations of active sites or substrate binding sites. Likewise, Trx-LIP4/lid3 showed a similar enantioselectivity to Trx-LIP4 (Table 11), and might assumed a similar catalytic machinery setting the chiral enantiopreference toward second alcohols. See Cygler *et al.* (1994) *J. Am. Chem. Soc.* 116: 3180-3186. In these cases, the effect of lid domain exchange could have been due to conformational changes, which had a subtle effect on the active site region and led to changes in substrate specificity and catalytic efficiency.

In conclusion, the lid domain has a significant effect on recombinant LIP enzyme catalytic efficiency, on the fatty acid chain length and desaturation selectivity of ester substrates, and on enantioselectivity. Therefore, the lid domain is a good choice for protein engineering to rationally design the biocatalytic properties of *C. rugosa* lipase for desired industrial applications. Site-directed mutagenesis on the lid region of LIP4 is currently underway to pinpoint the amino acid residues responsible for the substrate specificity, catalytic efficiency, enantioselectivity, and possibly enzyme stability.

Table 6. Comparison of overall and lid domain amino acid sequence identity of five *C. rugosa* lipase isoforms. Sequences were aligned by the CLUSTAL W program.

Pairwise identity (similarity) percentage of the full-length LIP proteins (534 aa).

	LIP1	LIP2	LIP3	LIP4	LIP5
LIP1	100(100)	80(89)	88(95)	81(90)	82(92)
LIP2		100(100)	82(89)	83(91)	77(88)
LIP3			100(100)	84(91)	86(94)
LIP4				100(100)	78(90)
LIP5					100(100)

Among five sequences: identity = 66%; similarity = 81%.

Pairwise identity (similarity) percentage of the changed lid domains (residue 63-94) of the wild type and chimeric LIP4.

	lid1	lid2	lid3	lid4	lid5
lid1	100(100)	56(75)	81(91)	50(72)	88(91)
lid2		100(100)	63(78)	53(81)	66(81)
lid3			100(100)	50(75)	88(94)
lid4				100(100)	56(75)
lid5					100(100)

Among five sequences: identity = 37.5%; similarity = 62.5%.

Table 7. Lipase activity of recombinant LIP4 expressed in *E. coli*

Enzyme	Specific activity	Relative activity
	(10 ³ U/mg) ^a	(%) ^b
Trx-LIP4	6.76	100.0
Trx-LIP4/lid1	1.03	15.2
Trx-LIP4/lid2	7.71	114.2
Trx-LIP4/lid3	8.90	131.7
Trx-LIP4/lid5	5.37	79.5

- a. One lipase unit (U) is defined as the enzyme amount which produces 1.0 micromole of butyric acid from tributyrin per min at pH 7.0 and 37°C.
- b. Relative activity is the ratio of the activity of each enzyme to that of the wild type LIP4.

Table 8. Hydrolysis of cholesterol esters and p-nitrophenyl esters of various chain-length fatty acids.

Enzyme	Cholesterol esterase activity (10 ⁻² U/mg) ^a			<i>p</i> -Nitrophenol esterase activity (U/mg) ^a		
	butyrate	caprate	stearate	butyrate	caprate	stearate
Trx-LIP4	6.2 (10) ^b	62.2 (100)	24.9 (40)	12.5 (44)	28.5 (100)	28.2 (99)
Trx-LIP4/lid1	0.0 (0)	3.7 (78)	4.8 (100)	0.7 (17)	5.1 (100)	0.6 (11)
Trx-LIP4/lid2	4.4 (9)	47.7 (100)	22.4 (47)	7.3 (26)	27.9 (100)	26.9 (97)
Trx-LIP4/lid3	0.8 (6)	14.5 (100)	8.9 (61)	1.2 (6)	18.6 (100)	5.0 (27)
Trx-LIP4/lid5	0.8 (11)	6.4 (89)	7.3 (100)	0.5 (5)	9.4 (100)	1.0 (11)

- a. One unit of activity(U) is the amount of enzyme necessary to hydrolyze 1.0 micromole of cholesteryl ester or *p*-nitrophenol ester per min at 37°C and pH 7.0.
- b. Parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

Table 9. Hydrolysis of cholesterol esters of various unsaturated fatty acids.

Enzyme	Cholesterol esterase activity		
	(10 ⁻² U/mg) ^a		
	cholesteryl stearate (18:0)	cholesteryl oleate (18:1)	cholesteryl linoleate (18:1)
Trx-LIP4	24.9 (7) ^b	354.6 (100)	242.0(68)
Trx-LIP4/lid1	4.8 (100)	1.5 (32)	2.5(53)
Trx-LIP4/lid2	22.4 (9)	244.7 (100)	148.9(61)
Trx-LIP4/lid3	8.9 (43)	20.7 (100)	18.6(90)
Trx-LIP4/lid5	7.3 (85)	8.5 (100)	6.5(76)

- a. One unit of activity (U) is defined as the amount of enzyme necessary to hydrolyze 1.0 micromole of cholesteryl linoleate per minute at 37°C and pH 7.0.
- b. The parentheses represent the ratio of the activity of each substrate to the highest one for the same enzyme.

Table 10. Kinetic parameters of a hydrolysis reaction using cholesteryl linoleate as the substrate.

Enzyme	M _r	V _{max}	K _m		k _{cat}	k _{cat} / K _m	
		10 ⁻³ μmol/min/mg	10 ⁻³ mM		min ⁻¹	mM ⁻¹ min ⁻¹	
Trx-LIP4	69680	2895 ± 117	104 ± 10	202	± 8.12	1940	± 139
LIP4	57051	1235 ± 32	41 ± 5	70	± 0.17	1740	± 298
Trx-LIP4/lid1	69717	28 ± 1	103 ± 5	2	± 0.04	19	± 0.47
Trx-LIP4/lid2	69877	1851 ± 24	74 ± 3	129	± 0.22	1751	± 64
Trx-LIP4/lid3	69757	231 ± 14	46 ± 1	16	± 0.17	349	± 7
Trx-LIP4/lid5	69797	70 ± 4.8	34 ± 1	5	± 0.01	147	± 3

a. The assay temperature was 37°C and pH was 7.0.

The concentrations of Trx-LIP4, LIP4, Trx-LIP4/lid1, Trx-LIP4/lid2, Trx-LIP4/lid3 and Trx-LIP4/lid5 were 29 nM, 39 nM, 11 nM, 86 nM, 58 nM and 66 nM, respectively. The values are averages from three independent experiments.

b. The molecular weights of recombinant proteins were predicted from the deduced amino acid sequences and those of commercial enzymes were determined from SDS-PAGE.

Table 11. The enantioselectivity of recombinant LIP4s expressed in *E.coli* and a commercial lipase (CRL) with (*d*)- and (*l*)-menthyl acetate as substrates.

Enzyme	$v(l)$ ^a ($\mu\text{mol/h/mg}$)	$v(d)$ ($\mu\text{mol/h/mg}$)	Enantioselectivity ^b $v(l)/v(d)$
Trx-LIP4	53.65 ± 4.10	1.69 ± 0.13	31.73
Trx-LIP4/lid1	2.15 ± 0.18	0.40 ± 0.06	5.35
Trx-LIP4/lid2	33.00 ± 3.48	2.89 ± 0.45	11.41
Trx-LIP4/lid3	54.11 ± 3.10	1.70 ± 0.23	31.81
Trx-LIP4/lid5	6.02 ± 0.57	0.48 ± 0.06	12.59
CRL	53.58 ± 3.38	42.65 ± 7.67	1.26

- a. Specific activity (v) is defined as the amount of (*d*)- or (*l*)-menthol released per mg of enzyme per hour at 30°C and pH 7.0.

OTHER EMBODIMENTS

All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.